FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
News|Slideshows|January 12, 2022
COVID-19 Vaccine Booster Shots: Questions Patients May Ask, Answers to Help Physicians Prepare
Author(s)Sydney Jennings
Advertisement
As COVID-19 vaccine booster doses become available and individuals start considering getting a booster, questions may arise regarding current guidance, formulation of the booster doses, and potential risks, to name a few. How should clinicians answer these questions and more? In the slides below, find answers from the recently updated guidance from the US
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Advertisement
Advertisement
Trending on Patient Care Online
1
Individualizing Obesity Treatment in Primary Care: An Expert Discussion
2
FDA Approves Insulin Efsitora Alfa-Gobe for Adults With Type 2 Diabetes
3
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
4
Type 2 Diabetes, Genetic Risk Linked to MASLD Cirrhosis Before Age 50
5